[go: up one dir, main page]

SG10201913159UA - Compositions for treatment of wet age-related macular degeneration - Google Patents

Compositions for treatment of wet age-related macular degeneration

Info

Publication number
SG10201913159UA
SG10201913159UA SG10201913159UA SG10201913159UA SG10201913159UA SG 10201913159U A SG10201913159U A SG 10201913159UA SG 10201913159U A SG10201913159U A SG 10201913159UA SG 10201913159U A SG10201913159U A SG 10201913159UA SG 10201913159U A SG10201913159U A SG 10201913159UA
Authority
SG
Singapore
Prior art keywords
compositions
treatment
macular degeneration
related macular
wet age
Prior art date
Application number
SG10201913159UA
Inventor
Anna Tretiakova
James M Wilson
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of SG10201913159UA publication Critical patent/SG10201913159UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG10201913159UA 2016-04-15 2017-04-15 Compositions for treatment of wet age-related macular degeneration SG10201913159UA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662323184P 2016-04-15 2016-04-15
US201662331100P 2016-05-03 2016-05-03
US201762442946P 2017-01-05 2017-01-05
US201762460515P 2017-02-17 2017-02-17
US201762466721P 2017-03-03 2017-03-03

Publications (1)

Publication Number Publication Date
SG10201913159UA true SG10201913159UA (en) 2020-02-27

Family

ID=59253994

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201808426XA SG11201808426XA (en) 2016-04-15 2017-04-14 Compositions for treatment of wet age-related macular degeneration
SG10201913159UA SG10201913159UA (en) 2016-04-15 2017-04-15 Compositions for treatment of wet age-related macular degeneration

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201808426XA SG11201808426XA (en) 2016-04-15 2017-04-14 Compositions for treatment of wet age-related macular degeneration

Country Status (10)

Country Link
US (2) US11197937B2 (en)
EP (1) EP3452103A1 (en)
JP (4) JP7046828B2 (en)
KR (2) KR20230130765A (en)
AU (2) AU2017248731B2 (en)
CA (1) CA3019426A1 (en)
IL (2) IL322403A (en)
MA (1) MA44873A (en)
SG (2) SG11201808426XA (en)
WO (1) WO2017180936A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
JP7088454B2 (en) 2015-12-30 2022-06-21 コディアック サイエンシーズ インコーポレイテッド Antibodies and antibody complexes
AU2018342094B2 (en) * 2017-09-27 2025-02-06 Regenxbio Inc. Treatment of ocular diseases with fully-human post-translationally modified anti-VEGF Fab
EP3697449A1 (en) * 2017-10-18 2020-08-26 REGENXBIO Inc. Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified vegf-trap
EP3717636B1 (en) * 2017-11-27 2023-03-08 4D Molecular Therapeutics Inc. Adeno-associated virus variant capsids and use for inhibiting angiogenesis
MY207644A (en) * 2017-12-19 2025-03-07 Akouos Inc Aav-mediated delivery of therapeutic antibodies to the inner ear
US20210093734A1 (en) * 2018-02-20 2021-04-01 The Trustees Of The University Of Pennsylvania Compositions for treatment of wet age-realted macular degeneration
CN112203679A (en) 2018-03-02 2021-01-08 科达制药股份有限公司 IL-6 antibodies and fusion constructs and conjugates thereof
JP2022049718A (en) * 2019-02-05 2022-03-30 アステラス製薬株式会社 Treatment of retinal degenerative disease by introduction of cx3cl1 gene using adeno-associated virus
JP2022521851A (en) * 2019-04-03 2022-04-12 レジェンクスバイオ インコーポレーテッド Gene therapy for eye pathology
CN114144197A (en) * 2019-04-24 2022-03-04 再生生物股份有限公司 Fully human post-translationally modified antibody therapeutics
WO2020243659A1 (en) * 2019-05-31 2020-12-03 University Of Florida Research Foundation, Incorporated Vector-based therapy for thyroid disease
KR20220051246A (en) * 2019-08-26 2022-04-26 리젠엑스바이오 인크. Treatment of diabetic retinopathy with fully human post-translational modified anti-VEGF Fab
JP2022552262A (en) 2019-10-07 2022-12-15 リジェネックスバイオ インコーポレイテッド Adeno-associated virus vector pharmaceutical compositions and methods
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021231491A1 (en) * 2020-05-11 2021-11-18 University Of Florida Research Foundation, Incorporated Disease correction by delivery of aav8 vectors expressing codon optimized naglu
WO2021231443A1 (en) * 2020-05-12 2021-11-18 The Trustees Of The University Of Pennsylvania Compositions useful in treatment of krabbe disease
WO2021255589A1 (en) * 2020-06-16 2021-12-23 Intas Pharmaceuticals Ltd. An anti-vegf scfab adeno-associated virus (aav) vector and uses thereof
WO2021255590A1 (en) * 2020-06-16 2021-12-23 Intas Pharmaceuticals Ltd. An anti-vegf scfv adeno-associated virus (aav) vector and uses thereof
CN113952473A (en) * 2020-07-21 2022-01-21 英斯培瑞有限公司 Compositions and methods for treating ocular diseases
KR20230088630A (en) * 2020-10-16 2023-06-20 자이로스코프 테라퓨틱스 리미티드 Nucleic acids encoding anti-VEGF entities and negative complement regulators and their use for the treatment of age-related macular degeneration
AR123948A1 (en) * 2020-10-28 2023-01-25 Regenxbio Inc VECTORIZED ANTI-TNF-α ANTIBODIES FOR OCULAR INDICATIONS
IL302282A (en) * 2020-10-29 2023-06-01 Regenxbio Inc Vectored TNF-alpha antagonists for ocular indications
MX2023006451A (en) 2020-12-01 2023-06-15 Akouos Inc CONSTRUCTIONS OF ANTI-VEGF ANTIBODIES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SCHWANNOMA.
JP2024505257A (en) 2021-02-01 2024-02-05 レジェンクスバイオ インコーポレーテッド Gene therapy for neuronal ceroid lipofuscinosis
WO2023150142A1 (en) * 2022-02-02 2023-08-10 Akouos, Inc. Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms
EP4504149A1 (en) 2022-04-06 2025-02-12 RegenxBio Inc. Pharmaceutical composition comprising a recombinant adeno-associated virus vector with an expression cassette encoding a transgene for suprachoidal administration
KR20250099772A (en) 2022-09-30 2025-07-02 리젠엑스바이오 인크. Treatment of ocular diseases using recombinant viral vectors encoding anti-VEGF FAB
WO2025073297A1 (en) * 2023-10-06 2025-04-10 甘李药业股份有限公司 Aav virus vector expressing anti-vegf fusion protein and use of aav virus vector
WO2025160405A1 (en) * 2024-01-24 2025-07-31 Duke University Compositions and methods for generation and secretion of aav particles

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994018317A1 (en) 1993-02-12 1994-08-18 The Board Of Trustees Of The Leland Stanford Junior University Regulated transcription of targeted genes and other biological events
AU719001B2 (en) 1994-12-29 2000-05-04 Massachusetts Institute Of Technology Chimeric DNA-binding proteins
WO1996041865A1 (en) 1995-06-07 1996-12-27 Ariad Gene Therapeutics, Inc. Rapamcycin-based regulation of biological events
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
AU9036198A (en) 1997-08-26 1999-03-16 Ariad Gene Therapeutics, Inc. Fusion proteins comprising a dimerization, trimerization or tetramerization domain and an additional heterologous transcription activation, transcription repression, dna binding or ligand binding domain
CA2303482A1 (en) 1997-08-27 1999-03-04 Ariad Gene Therapeutics, Inc. Chimeric transcriptional activators and compositions and uses related thereto
WO1999036553A2 (en) 1998-01-15 1999-07-22 Ariad Gene Therapeutics, Inc. Regulation of biological events using multimeric chimeric proteins
WO1999041258A1 (en) 1998-02-13 1999-08-19 President And Fellows Of Harvard College Novel dimerizing agents, their production and use
CA2379166C (en) 1999-08-09 2013-03-26 Targeted Genetics Corporation Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs
US7067526B1 (en) 1999-08-24 2006-06-27 Ariad Gene Therapeutics, Inc. 28-epirapalogs
WO2001029242A2 (en) 1999-10-21 2001-04-26 Monsanto Company Post-translational modification of recombinant proteins produced in plants
GB2362884A (en) 2000-05-30 2001-12-05 Isis Innovation Extended duration of airway gene therapy
CA2417508A1 (en) 2000-07-26 2002-01-31 Ludwig Institute For Cancer Research Glycosylated vegf-b and method for increasing the amount of soluble vegf-b
MX346493B (en) 2001-11-13 2017-03-21 Univ Pennsylvania Method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby.
JP4810062B2 (en) 2001-12-17 2011-11-09 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Sequence of adeno-associated virus (AAV) serotype 8
US20030224397A1 (en) 2002-02-11 2003-12-04 Genentech, Inc. Antibody variants with faster antigen association rates
US20040208847A1 (en) 2003-03-28 2004-10-21 Fabienne Rolling Method and vectors for selectively transducing retinal pigment epithelium cells
CN102199626B (en) 2003-09-30 2015-06-24 宾夕法尼亚大学托管会 Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses therefor
EP2383346B1 (en) 2005-04-07 2014-10-08 The Trustees of the University of Pennsylvania Modified AAVrh.64 capsids, compositions containing same and uses thereof
EP1777906A1 (en) 2005-06-09 2007-04-25 Matsushita Electric Industrial Co., Ltd. Amplitude error compensating apparatus and orthogonality error compensating apparatus
RU2498991C2 (en) 2007-10-30 2013-11-20 Дженентек, Инк. Purification of antibodies with cation-exchange chromatography
AR069501A1 (en) 2007-11-30 2010-01-27 Genentech Inc ANTI-VEGF ANTIBODIES (VASCULAR ENDOTELIAL GROWTH FACTOR)
KR101010352B1 (en) 2008-05-30 2011-01-25 삼성중공업 주식회사 Power control device and method
CA2742968C (en) 2008-11-07 2020-06-09 Fabrus Llc Combinatorial antibody libraries and uses thereof
US8734809B2 (en) * 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
JP5785941B2 (en) 2009-06-17 2015-09-30 アッヴィ・バイオセラピューティクス・インコーポレイテッド Anti-VEGF antibodies and uses thereof
US8927514B2 (en) 2010-04-30 2015-01-06 City Of Hope Recombinant adeno-associated vectors for targeted treatment
US8628966B2 (en) 2010-04-30 2014-01-14 City Of Hope CD34-derived recombinant adeno-associated vectors for stem cell transduction and systemic therapeutic gene transfer
US8663624B2 (en) * 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
CN103189507A (en) 2010-10-27 2013-07-03 学校法人自治医科大学 Adeno-associated virus particles for gene delivery into nervous system cells
WO2012109570A1 (en) 2011-02-10 2012-08-16 The University Of North Carolina At Chapel Hill Viral vectors with modified transduction profiles and methods of making and using the same
BR112013021494B1 (en) * 2011-02-22 2021-09-08 California Institute Of Technology VIRAL VECTOR, ISOLATED POLYNUCLEOTIDE, USE OF A RECOMBINANT ADENO-ASSOCIATED VIRUS (AAV) AND METHOD TO PRODUCE THE SAME
JP6072772B2 (en) 2011-04-22 2017-02-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Adeno-associated virus virions with mutant capsids and methods of use thereof
EP2559443A1 (en) 2011-08-16 2013-02-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of an ocular disease in a subject
EP3795581A3 (en) 2011-08-24 2021-06-09 The Board of Trustees of the Leland Stanford Junior University New avv capsid proteins for nucleic acid transfer
US20130090375A1 (en) * 2011-10-06 2013-04-11 Cornell University Virus-mediated delivery of bevacizumab for therapeutic applications
JP6385920B2 (en) 2012-05-09 2018-09-05 オレゴン ヘルス アンド サイエンス ユニバーシティー Adeno-associated virus plasmid and vector
TWI702955B (en) 2012-05-15 2020-09-01 澳大利亞商艾佛蘭屈澳洲私營有限公司 Treatment of amd using aav sflt-1
BR112015010566A2 (en) 2012-11-08 2017-07-11 Clearside Biomedical Inc methods and devices for the treatment of eye disease in human subjects
DK2954051T3 (en) 2013-02-08 2019-07-08 Univ Pennsylvania MODIFIED KAPSID FOR TRANSFER FOR TREATMENT OF THE NETWORK
JP2016514152A (en) 2013-03-13 2016-05-19 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア Adeno-associated virus vector and method of use thereof
JP6591956B2 (en) 2013-03-15 2019-10-16 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Compositions and methods for treating MPS1
WO2015038958A1 (en) 2013-09-13 2015-03-19 California Institute Of Technology Selective recovery
PL3459965T3 (en) 2013-10-11 2021-07-26 Massachusetts Eye & Ear Infirmary Methods of predicting ancestral virus sequences and uses thereof
JP6818551B2 (en) 2013-12-03 2021-01-20 ホオキパ バイオテック ジーエムビーエイチ CMV vaccine
GB201403684D0 (en) 2014-03-03 2014-04-16 King S College London Vector
US11555059B2 (en) 2014-04-25 2023-01-17 The Trustees Of The University Of Pennsylvania LDLR variants and their use in compositions for reducing cholesterol levels
US10746742B2 (en) 2014-04-25 2020-08-18 Oregon Health & Science University Methods of viral neutralizing antibody epitope mapping
CN106470736B (en) 2014-05-13 2021-05-28 宾夕法尼亚州大学信托人 Compositions comprising AAVs expressing diabody constructs and uses thereof
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
US9840553B2 (en) * 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US10064752B2 (en) 2014-09-11 2018-09-04 Orbit Biomedical Limited Motorized suprachoroidal injection of therapeutic agent
WO2016134375A1 (en) 2015-02-20 2016-08-25 University Of Iowa Research Foundation Methods and compositions for treating genetic eye diseases
EP3307310A2 (en) * 2015-05-13 2018-04-18 The Trustees Of The University Of Pennsylvania Aav-mediated expression of anti-influenza antibodies and methods of use thereof
EP3344294A4 (en) 2015-08-31 2019-03-20 The Trustees Of The University Of Pennsylvania ANTI-VEGF CHIMERIC VACCINE FOR THE TREATMENT OF CANCER IN CANINE
GB201519086D0 (en) 2015-10-28 2015-12-09 Syncona Partners Llp Gene Therapy
EP3400014A1 (en) 2016-01-08 2018-11-14 Clearside Biomedical, Inc. Methods and devices for treating posterior ocular disorderswith aflibercept and other biologics
KR20190003556A (en) 2016-04-15 2019-01-09 리젠엑스바이오 인크. Treatment of eye diseases with modified anti-VEGF Fabs after fully-humanized translation
AU2018342094B2 (en) 2017-09-27 2025-02-06 Regenxbio Inc. Treatment of ocular diseases with fully-human post-translationally modified anti-VEGF Fab
JP2022521851A (en) 2019-04-03 2022-04-12 レジェンクスバイオ インコーポレーテッド Gene therapy for eye pathology

Also Published As

Publication number Publication date
JP7492556B2 (en) 2024-05-29
JP7111924B2 (en) 2022-08-02
KR102574810B1 (en) 2023-09-08
JP2024105617A (en) 2024-08-06
SG11201808426XA (en) 2018-10-30
WO2017180936A1 (en) 2017-10-19
IL322403A (en) 2025-09-01
US20220288238A1 (en) 2022-09-15
US11197937B2 (en) 2021-12-14
US20190381194A1 (en) 2019-12-19
KR20230130765A (en) 2023-09-12
JP2022141856A (en) 2022-09-29
KR20190031196A (en) 2019-03-25
IL262207A (en) 2018-11-29
JP2019518427A (en) 2019-07-04
JP2022084809A (en) 2022-06-07
NZ746729A (en) 2023-08-25
AU2017248731B2 (en) 2024-08-29
MA44873A (en) 2019-03-13
AU2017248731A1 (en) 2018-10-18
AU2024216307A1 (en) 2024-10-17
CA3019426A1 (en) 2017-10-19
EP3452103A1 (en) 2019-03-13
JP7046828B2 (en) 2022-04-04
IL262207B1 (en) 2025-09-01

Similar Documents

Publication Publication Date Title
SG10201913159UA (en) Compositions for treatment of wet age-related macular degeneration
IL276777A (en) Compositions for treatment of wet age-related macular degeneration
ZA201901279B (en) Compositions and methods for treatment of neurological disorders
SG11201705093UA (en) Composition for treating il-6-related diseases
IL239836A0 (en) Age- related macular degeneration treatment
IL246791A0 (en) Compositions and methods for treating ocular diseases
IL267146A (en) Novel method of treating macular degeneration
IL249938B (en) Compositions of antiviral agents for prophylaxis treatment
EP3697920A4 (en) Compositions and methods for treating age-related macular degeneration
ZA201904660B (en) Treatment of aqueous compositions including fines
EP3160460A4 (en) Ketobutyrate compounds and compositions for treating age-related symptoms and diseases
SG11201606101WA (en) Compositions and methods for treating and preventing macular degeneration
SG11201704829QA (en) Methods and compositions for treating brain diseases
IL249640A0 (en) Compositions for the treatment of epistaxis
GB201612043D0 (en) Composition for treatment of disorders
ZA201904051B (en) Peptide for treating age-related macular degeneration
PT3142641T (en) Formulations for treatment of hyperthyroidism
GB201616158D0 (en) Age-related macular degeneration
ZA201803097B (en) High-dose statins for age-related macular degeneration
IL252543A0 (en) Compositions for treatment of retinal degenerative diseases
SMT202300229T1 (en) Compositions for treating ophthalmic conditions
EP3849596C0 (en) COMPOSITIONS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION
HK1262141A1 (en) Compositions for treatment of wet age-related macular degeneration
HK40043288A (en) Compositions for treatment of wet age-related macular degeneration
HK40035997A (en) Compositions and methods for treating age-related macular degeneration